Table 1.
Participant Characteristics
| Total Sample | Chronic Pain | No Chronic Pain | p-valuesa | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| (N=179) | Total (N=75) | Methadone (N=49) | Buprenorphine (N=26) | Total (N=104) | Methadone (N=70) | Buprenorphine (N=34) | Pain | OMTb | |
| Age (yrs) | 45.9 (10.3) | 45.9 (10.4) | 46.7 (11.3) | 44.5 (8.7) | 45.9 (10.1) | 45.4 (10.2) | 47.1 (10.0) | 0.67 | 0.89 |
| Male (%) | 51.9 | 51.4 | 46.8 | 60.0 | 52.5 | 53.7 | 50.0 | 0.99 | 0.75 |
| Caucasian (%) | 43.3 | 44.6 | 47.9 | 38.5 | 41.4 | 42.4 | 39.4 | 0.78 | 0.52 |
| Hispanic (%) | 3.0 | 0.0 | 0.0 | 0.0 | 5.9 | 5.8 | 6.1 | 0.04 | 0.99 |
| Never Married (%) | 54.9 | 52.0 | 57.1 | 42.3 | 57.8 | 53.6 | 66.7 | 0.45 | 0.99 |
| Employed (%) | 17.2 | 20.0 | 16.3 | 26.9 | 14.4 | 11.4 | 20.6 | 0.57 | 0.32 |
| Health Insurance (%) | 89.0 | 93.3 | 91.1 | 96.2 | 84.7 | 84.2 | 85.3 | 0.87 | 0.02 |
| HIV (%) | 15.1 | 17.6 | 12.5 | 26.9 | 12.6 | 8.7 | 20.6 | 0.44 | 0.34 |
| Hepatitis C (%) | 44.0 | 47.3 | 52.1 | 38.5 | 40.6 | 41.8 | 38.2 | 0.39 | 0.03 |
| Injection Drug User (%) | 64.5 | 64.0 | 73.5 | 46.2 | 65.0 | 69.6 | 55.9 | 0.99 | 0.01 |
| Duration in OMT (yrs) | 5.2 (5.9) | 4.8 (5.5) | 5.5 (5.6) | 3.5 (4.8) | 5.6 (6.3) | 6.2 (6.8) | 4.2 (5.1) | 0.47 | 0.03 |
| SOWS Score (range 0–64) | 14.8 (13.9) | 16.08 (14.3) | 16.6 (13.8) | 15.1 (15.5) | 13.4 (13.5) | 15.1 (13.8) | 9.9 (12.2) | 0.19 | 0.14 |
| SCL-10R Total Score (range 0–40) | 10.1 (10.0) | 10.9 (10.0) | 11.2 (9.5) | 10.9 (11.0) | 9.2 (10.0) | 9.9 (10.5) | 7.9 (9.1) | 0.19 | 0.49 |
Values represent Mean (Standard Deviation) unless otherwise noted.
a
Results based on Fisher’s exact tests for categorical variables and ANOVAs for continuous variables
b
OMT= opioid maintenance treatment type (methadone vs. buprenorphine)